Eikon Therapeutics (EIKN) stock, explained like you're 5

Is Eikon Therapeutics a small, medium or large cap company?

No. Eikon Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 405 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Eikon Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves EIKN stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• A prostate cancer drug candidate targets variants tied to treatment resistance. Eikon filed it with the FDA. (Stock Titan)
• HC Wainwright & Co. initiates coverage of Eikon Therapeutics with Buy rating, $23 price target (TradingView)
• Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates? (Yahoo Finance)
• Eikon Therapeutics, Inc. Submits IND For Novel Androgen Receptor Antagonist EIK1006 In Prostate Cancer (www.marketscreener.com)
• Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Oct 2026 (MarketBeat)

Key terms to know before you follow EIKN

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility